您好,歡迎光臨艾維締科技懷來有限公司官方網(wǎng)站!
熱線:0313-5935521
IVDPlus 經(jīng)FDA驗證的藥物庫
DiscoveryProbe™ FDA批準的藥物庫包括2320種FDA批準的藥物,用于高通量篩選(HTS)和高含量篩選(HCS)。它可用于為老藥尋找新的目標。這些藥物的生物活性和安全性已被臨床試驗所證實。由于它們都是FDA批準的藥物,所篩選的藥物可以直接用于臨床試驗。
Catalog No. | Product Name | Summary | Targets | CAS Number | Smiles |
A3298 | Cetirizine | Antihistamine | Neuroscience|Histamine Receptor | 83881-51-0 | C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl |
A3789 | Salmeterol xinafoate | β2-adrenergic receptor agonist | GPCR/G protein|Adrenergic Receptor | 94749-08-3 | C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O.C1=CC=C2C(=C1)C=CC(=C2O)C(=O)O |
A4363 | Fluvastatin Sodium | HMG-CoA reductase inhibitor | Metabolism|HMG-CoA Reductase | 93957-55-2 | CC(C)N1C2=CC=CC=C2C(=C1C=CC(CC(CC(=O)[O-])O)O)C3=CC=C(C=C3)F.[Na+] |
A4370 | Moclobemide (Ro 111163) | Reversible inhibitor of MAO-A | Metabolism|MAO | 71320-77-9 | C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl |
A8252 | Nintedanib(BIBF 1120) | VEGFR/PDGFR/FGFR inhibitor | Tyrosine Kinase/Adaptors|PDGFR | 928326-83-4 | CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)NC(=C3C4=C(C=C(C=C4)C(=O)OC)NC3=O)C5=CC=CC=C5 |
B1792 | Montelukast Sodium | Leukotriene receptor antagonist | GPCR/G protein|CysLT1 receptor | 151767-02-1 | CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)[O-])O.[Na+] |
N1674 | Piperine | MAPK inhibitor | Natural Products | 94-62-2 | C1CCN(CC1)C(=O)C=CC=CC2=CC3=C(C=C2)OCO3 |
N1707 | Coumarin | Precursor in chemical reaction | Natural Products | 91-64-5 | C1=CC=C2C(=C1)C=CC(=O)O2 |
Form | Pre-dissolved DMSO solutions | Stability | Solution: -20°C for 12 months, -80°C for 24 months |
Packaging | 96-well Microplate format with peelable foil seal and EVA cap (20 μL/well, 10 mM DMSO); 96-well DeepWell format with peelable foil seal and EVA cap (100 μL/well, 10 mM DMSO); 96-well rack with Matrix 2D Barcoded ScrewTop Storage tubes (250 μL or 100 μL/well, 10 mM DMSO). |
||
Shipping Condition | Evaluation sample solution: ship with blue ice All other available size: ship with RT, or blue ice upon request |
1. Barrows NJ, Campos RK, Powell ST, et al. A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection. Cell Host Microbe. 2016 Jul 27. pii: S1931-3128(16)30303-1.
Abstract
We interrogated a FDA-approved chemicals library for their ability to block infection of human HuH-7 cells by a newly isolated ZIKV strain (ZIKV MEX_I_7). In our in vitro screening assay, more than 20 out of 774 tested compounds reduced ZIKV infection. Then these compounds were further validated for inhibition of ZIKV infection in human neural, cervical and placental stem cell lines, as well as primary human amnion cells. We found that others that had no previously known antiviral activity (e.g., daptomycin) and anti-flaviviral drugs (e.g., bortezomib and mycophenolic acid) were identified as inhibitors of ZIKV infection. There were several drugs that reduced ZIKV infection across multiple cell types, which could be tested in clinical studies of ZIKV infection and provided small molecules to study ZIKV pathogenesis.
2. Stavrovskaya IG, Narayanan MV, Zhang W, et al. Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology. J Exp Med. 2004 Jul 19;200(2):211-22.
Abstract
Mitochondria are a major checkpoint in several pathways leading to neuronal cell death and the mitochondrial permeability transition (mPT) may be critical in stroke-related injury. In order to prove this hypothesis, 1,040 FDA-approved drugs and other bioactive compounds were tested as potential mPT inhibitors. We found that 28 structurally related drugs, including tricyclic antipsychotics and antidepressants, capable of delaying the mPT. Clinically achievable doses of promethazine inhibited mPT and were protective in both in vitro and mouse models of stroke. Also, promethazine protected primary neuronal cultures subjected to oxygen-glucose deprivation and reduced neurological impairment and infarct size in mice subjected to middle cerebral artery occlusion/reperfusion. These results provided a class of safe, tolerable drugs for stroke and neurodegeneration and also provided new tools for understanding mitochondrial roles in neuronal cell death.
產(chǎn)品組分
內(nèi)容 |
型號 |
規(guī)格 | 價格 |
儲存溫度 |
IVDPlus 經(jīng)FDA驗證的藥物庫 | L1021-01 | 20ul/孔(10mM 溶液)/96微孔板 | 0.00 | -20°C |
IVDPlus 經(jīng)FDA驗證的藥物庫 | L1021-02 | 100ul/孔(10mM 溶液)/96深孔板 | 0.00 | -20°C |
IVDPlus 經(jīng)FDA驗證的藥物庫 | L1021-03 | 100ul/孔(10mM 溶液)/帶蓋96孔板 | 0.00 | -20°C |
IVDPlus 經(jīng)FDA驗證的藥物庫 | L1021-04 | 250ul/孔(10mM 溶液)/帶蓋96孔板 | 0.00 | -20°C |
操作手冊 |
1 | 1 |
常溫 |
文件資源
文件下載 | 文件內(nèi)容 | 資源說明 |
L1021-IVDPlus 經(jīng)FDA驗證的藥物庫 | 操作手冊 | |
L1021-IVDPlus 經(jīng)FDA驗證的藥物庫相關單頁 | 宣傳單頁 |
注意事項
保存建議 | 廠家推薦藍冰運輸。當您收到產(chǎn)品后,按照說明書建議保存于-20°C。 |
FAQ
1. James M. Havrilla, Cong Liu, et al. "PhenCards: a data resource linking human phenotype information to biomedical knowledge." Genome Med. 2021 May 25;13(1):91. PMID:34034817
2. Gur D, Chitlaru T, Mamroud E, et al. "Screening of an FDA-Approved Library for Novel Drugs against Y. pestis." Antibiotics (Basel). 2021 Jan 3;10(1):40. PMID:33401634
3. Moore JA, Meakin M, et al. "Effects of Caspofungin, Tolcapone, and Other FDA-Approved Medications on MRSA Susceptibility to Vancomycin." J Glob Antimicrob Resist. 2020;S2213-7165(20)30078-3. PMID:32247076
4. Turner TH, Alzubi MA, et al. "Identification of synergistic drug combinations using breast cancer patient-derived xenografts." Sci Rep. 2020 Jan 30;10(1):1493. PMID:32001757
5. Yang JJ, Han Y, et al. "Streamlined MRM method transfer between instruments assisted with HRMS matching and retention-time prediction." Anal Chim Acta. 2020;1100:88–96. PMID:31987156
推薦產(chǎn)品
免責申明:本網(wǎng)站銷售的所有產(chǎn)品均不得用于人類或動物之臨床診斷或治療,僅可用于工業(yè)或者科研等非醫(yī)療目的。(獲得國家相關部門批準的產(chǎn)品除外)
版權所有:艾維締科技懷來有限公司 備案號:冀ICP備20011415號